TI was defined as a weighted average hemoglobin (Hb) >= 9 grams per deciliter (g/dL) without any packed red blood cell (pRBC) transfusions for a continuous period of >= 12 months at any time during the study after drug product infusion.

Transplant Population (TP) included all participants who received beti-cel. All participants in the TP (23 participants) were evaluable for TI.

TI was defined as a weighted average hemoglobin (Hb) >= 9 grams per deciliter (g/dL) without any packed red blood cell (pRBC) transfusions for a continuous period of >= 12 months at any time during the study after drug product infusion. Percentage of participants who met the definition of TI at Month 24 were evaluated

TP included all participants who received beti-cel. All participants in the TP (23 participants) were evaluable for TI.

Duration of TI was calculated as the time from the start of TI (that is (i.e.), first Hb >=9 with no transfusions in the preceding 60 days) up to the last available Hb at which the TI criteria are still met using Kaplan-Meier methodology. Duration of TI from start of TI up to Month 24 months was reported.

TP included all participants who received beti-cel. All participants in the TP (23 participants) were evaluable for TI. Here, "Overall number of participants analyzed" signifies those participants who achieved TI (i.e. 21 participants as 2 participants did not achieve TI).

Time from drug product infusion to achievement of TI was calculated as the time from drug product infusion to the first hemoglobin at which a participant can be declared as TI (that is to 'start of TI + >= 12 months', dependent on Hb lab schedule).

TP included all participants who received beti-cel. All participants in the TP (23 participants) were evaluable for TI. Here, "Overall number of participants analyzed" signifies those participants who achieved TI (i.e. 21 participants as 2 participants did not achieve TI).

Weighted average Hb was defined as the weighted average of Hb values without any pRBC transfusions in the proceeding 60 days. The ratio of the time between two Hb values and the time between the first and the last Hb values was used as the weight for calculation.

TP included all participants who received beti-cel. All participants in the TP (23 participants) were evaluable for TI. Here, "Overall number of participants analyzed" signifies those participants who achieved TI (i.e. 21 participants as 2 participants did not achieve TI).

Percentage of participants reduction in the annualized mL/kg pRBCs transfused from 12 months post-drug product infusion through Month 24 (approximately a 12-month period) of at least 50%, 60%, 75%, 90% or 100% compared to the annualized mL/kg pRBC transfusion requirement during the 24 months prior to enrollment.

TP included all participants who received beti-cel.

Annualized number of pRBC transfusions from 12 months post-drug product infusion through Month 24 were reported.

TP included all participants who received beti-cel.

Annualized volume of pRBC transfusions from 12 months post-drug product infusion through Month 24 was reported.

TP included all participants who received beti-cel.

Time from drug product infusion to last pRBC transfusion was reported.

TP included all participants who received beti-cel.

Time From Last pRBC Transfusion to Month 24 was reported.

TP included all participants who received beti-cel. Data are presented through the Month 24 Visit based on calendar dates and including visit windows. Notably due to institutional COVID-19 restrictions and scheduling conflicts one participant had a Month 24 visit 42 days out of this window.

The weighted average nadir Hb was defined as the most recent Hb prior to each pRBC transfusion, on the day of transfusion or within 3 days and, if there was a period of more than 60 days without transfusion, all Hb records between Day 61 and last follow-up or next transfusion (inclusive) was included. The weighted average nadir Hb during the period of 12 months post-drug product infusion to Month 24 was compared to the weighted average nadir Hb during the 24 months prior to enrollment.

TP included all participants who received beti-cel.

Unsupported total Hb level was defined as the total Hb measurement level without any acute or chronic pRBC transfusions within 60 days prior to the measurement date.

TP included all participants who received beti-cel. Here, "Overall number of participants analyzed" signifies those participants who had a least 1 unsupported total Hb measurement during Study HGB-207 and "number analyzed" signifies those participants who had an unsupported total Hb measurement at the specific timepoint.

The number of participants with unsupported total Hb levels (>=10 g/dL, >=11 g/dL, >=12 g/dL, >=13 g/dL, and >=14 g/dL) meeting the thresholds were reported at at Months 6, 9, 12, 18 and 24. Participants were evaluable if they had an unsupported total Hb measurement at the specific timepoint, where unsupported total Hb level is defined as the total Hb measurement level without any acute or chronic pRBC transfusions within 60 days prior to the measurement date.

TP included all participants who received beti-cel. Here, "Overall number of participants analyzed" signifies those participants who had a least 1 unsupported total Hb measurement during Study HGB-207 and "number analyzed" signifies those participants who had an unsupported total Hb measurement at the specific timepoint.

Percentage of participants who have not received chelation therapy for at least 6 months following drug product infusion were reported.

TP included all participants who received beti-cel.

Time from last iron chelation use to last follow-up to 24 months was reported. Participants were evaluable for this outcome if they had not received iron chelation therapy for at least 6 months following drug product infusion.

TP population. Here, "Overall number of participants analyzed" signifies those participants who have not received chelation therapy for at least 6 months following drug product infusion. Data are presented through the Month 24 Visit based on calendar dates and including visit windows. Notably due to institutional COVID-19 restrictions and scheduling conflicts one participant had a Month 24 visit 42 days out of this window.

Therapeutic phlebotomy could be used in lieu of chelation in participants who had Hb consistently >= 11 g/dL and who were no longer receiving regular transfusions, at the discretion of the investigator. Percentage of participants who used therapeutic phlebotomy post DP infusion for up to Month 24 were reported.

TP included all participants who received beti-cel.

Annualized phlebotomy therapy usage (number of procedures per year, calculated from DP infusion through last follow-up) were reported.

TP included all participants who received beti-cel. Here, "Overall number of participants analyzed" signifies those participants who received therapeutic phlebotomy.

Change From Baseline in liver Iron Content by Magnetic Resonance Imaging (MRI) at Months 12 and 24 were reported.

TP included all participants who received beti-cel. Participants were evaluable for this outcome if they had available liver iron content measurements at baseline and at the applicable follow-up timepoints. Here, "number of participants analyzed" signifies those participants who had LIC data available at Baseline, Months 12 and 24.

Change From Baseline in Cardiac T2* on MRI at baseline, Month 12 and 24 was reported.

TP included all participants who received beti-cel. Participants were evaluable for this outcome if they had available cardiac T2* measurements at baseline and at the applicable follow-up timepoints. Here, "Overall number of participants analyzed" signifies those participants who had Cardiac T2* data available at Baseline, Months 12 and 24 and "number analyzed" signifies those participants at specific timepoint.

Serum ferritin was commonly used for an indirect estimation of body iron stores. Although sensitive, it is not specific for iron overload as it can be elevated in a variety of infectious and inflammatory states, and in the presence of cytolysis. Change from baseline in serum ferritin at Months 12 and 24 was reported.

TP included all participants who received beti-cel. Participants were evaluable for this endpoint if they had available serum ferritin measurements at baseline and at the applicable follow-up timepoints. Here, "number analyzed" signifies those participants who were evaluable at specific timepoint.

PedsQL GCS designed to measure health-related quality of life in pediatric and adolescents (2 to 18 years). It encompassed 4 dimensions of functioning (physical [8 items], emotional [5 items], social [5 items], school [3 items]). Age groups: Toddler (2-4 years), Young pediatric (5-7 years), Pediatric (8-12 years), Teens (13-18 years). The questionnaire was also completed by parent/caregiver to assess parents' perceptions of their children's quality of life. The Toddler group consisted of 21 items, using a 5-point Likert scale (0 to 4); all other groups consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for young pediatric, a 5-point Likert scale for pediatric and teens groups. All reported scores were transformed on a scale from 0 to 100 for each domain where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores correspond with higher quality of life.

TP included all participants who received beti-cel. Here, "Overall number of participants analyzed" signifies those participants who were evaluable for this outcome measure and "number analyzed" signifies those participants who were <18 years at specific timepoint.

EQ-5D is a validated, standardized, generic instrument that was most widely used preference based health related quality of life questionnaire in cost effectiveness and health technologies assessment. EQ-5D-Y was a version of instrument specifically developed and validated for use by youths aged 12 through 17 years. The EQ-5D-Y visual analog scale (VAS) consisted of a 20-cm vertical VAS, with anchors of 0 ("worst imaginable health state") and 100 ("best imaginable health state"). Respondents were asked to rate their own health state today by drawing a line from a box containing these words to the point on the scale that they felt most accurately reflected their current health state. The VAS was reported (raw data) on a scale of 0-100 where 0= death and 100= perfect health. Higher scores equated to better outcomes.

TP included all participants who received beti-cel. Here, "Overall number of participants analyzed" signifies those participants who were evaluable for this outcome measure and "number analyzed" signifies those participants who were 11 to <18 years at specific timepoint.

EQ-5D is a validated, standardized, generic instrument that was most widely used preference based health related quality of life (HRQoL) questionnaire in cost effectiveness and health technologies assessment. Participants age >=18 at time of informed consent were eligible to complete the EQ-5D-3L which is a visual analog scale (VAS) which consists of a 20-cm vertical VAS, with anchors of 0 ("worst imaginable health state") and 100 ("best imaginable health state"). Respondents were asked to rate their own health state today by drawing a line from a box containing these words to the point on the scale that they feel most accurately reflects their current health state.

TP included all participants who received beti-cel. Here, "Overall number of participants analyzed" signifies those participants who were evaluable for this endpoint and number analyzed signifies those participants who were >= 18 years at specific timepoint.

FACT-BMT is assessed bone marrow transplant related quality of life in adults. It. Total score was sum of sub-scale scores for 5 domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, and Bone Marrow Transplantation Subscale. Each item scored on a 5-point Likert scale based on participant agreement with each statement: 0 for "not at all," 1 for "a little bit," 2 for "somewhat," 3 for "quite a bit," and 4 for "very much. Reported scores were transformed as follows: After taking into account reverse scores for questions constructed in negative form, subscale score for each domain was calculated by multiplying sum of item scores by number of items in subscale, then dividing by number of items answered. Total score was sum of subscale total added together and ranges from 0-148. Higher scores corresponded with higher quality of life.

TP included all participants who received beti-cel. Here, "Overall number of participants analyzed" signifies those participants who were >= 18 years for this outcome measure.

SF-36 was designed to measure health-related quality of life in adults. The instrument consisted of 36 items, were aggregated into 8 multi-item scales (physical functioning [1=yes, limited a lot to 3=no, not limited at all], role-physical [1=all of time to 5=none of time], bodily pain [1=very severe to 6=none], general health [1=poor to 5=excellent], vitality [1=none of time to 5=all of time], social functioning [1=all of time: to 5=none of time], role emotional [1=all of time to 5=none of time] and mental health [1=all of time to 5=none of the time]). Four domains comprised physical component summary (PCS) score (physical functioning, role-physical, bodily pain, general health) and remaining 4 domains comprised mental component summary (MCS) score (vitality, social functioning, role-emotional, mental health). Reported summary scores were transformed on a scale from 0 to 100. Higher scores corresponded with higher quality of life.

TP included all participants who received beti-cel. Here, "Overall number of participants analyzed" signifies those participants who were >= 18 years for this outcome measure.